Clinical trials
Macular Degeneration clinical trials
Below are recruiting macular degeneration clinical trials, each written for real people, not researchers. We’re tracking 164 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06718816Recruiting
Long-term follow-up of AL-001 eye injection for wet AMD
This trial is a long-term follow-up for people who already received the AL-001 eye injection for wet age-related macular degeneration (wet AMD) in an earlier study. It will check how you are doing over time.
Beijing, Beijing MunicipalityAges 50 years+ - NCT07582042Recruiting
Vision testing in geographic atrophy treated with pegcetacoplan
This study tests a specialized vision-testing method in people with geographic atrophy (a type of dry age-related macular degeneration) who are already receiving pegcetacoplan injections. The goal is to better understand how this treatment affects vision in different parts of the eye.
Salt Lake City, UtahAges 65–90 - NCT07577219Recruiting
Vision Training With Feedback for Central Vision Loss
This study teaches people with central vision loss (blurred or missing spots in the middle of vision) how to use their remaining side vision better, using special training with audio and visual feedback. It may help improve how well you can read and recognize faces.
Boston, MassachusettsAges 14 years+ - NCT07556406Recruiting
Eye imaging study for age-related macular degeneration
This study uses specialized eye imaging to track changes in geographic atrophy, a type of vision loss from macular degeneration. Researchers will use new imaging techniques to better understand how this condition progresses and how treatments work.
San Francisco, CaliforniaAges 55 years+ - NCT07555574Recruiting
New imaging technology to see retinal structures clearly
This research study tests a new camera technology that takes detailed pictures of the back of your eye (retina) to better understand eye diseases. Researchers want to compare images from people with eye conditions like diabetes-related eye disease, glaucoma, or age-related macular degeneration with healthy volunteers to see how the new imaging works.
Melbourne, VictoriaAges 18 years+ - NCT07550777Recruiting
Heart Health and Eye Injections Study
This study looks at how repeated eye injections of a drug called bevacizumab affect chemicals in your blood that relate to heart health and inflammation. Researchers want to understand if these eye injections might impact your cardiovascular risk.
Erzurum, ErzurumAges 50–80 - NCT07531927Recruiting
Electrical Stimulation for Geographic Atrophy Vision Loss
This study tests whether gentle electrical stimulation applied to the eye can help slow vision loss from geographic atrophy, a common cause of blindness in older adults. The treatment uses a special device to stimulate the retina (the light-sensing tissue in the back of your eye).
HamburgAges 60 years+ - NCT07515521Recruiting
Vision and Imaging Tests for Early and Intermediate AMD
This study tests new ways to measure vision and take detailed eye images in people with age-related macular degeneration (AMD), a common eye condition affecting central vision. The goal is to develop better tools for future AMD treatment trials.
BonnAges 18 years+ - NCT04985487Recruiting
Safety follow-up for brolucizumab in neovascular AMD
This study tracks the real-world safety of brolucizumab in adults with neovascular age-related macular degeneration (nAMD). If you’re already prescribed this medicine, the study may help confirm it continues to be safe and well-tolerated over time.
Daegu, Dalseo GuAges 18–100 - NCT07461441RecruitingPhase 3
Personalized faricimab for new polypoidal choroidal vasculopathy
This study tests a personalized treatment plan using an investigational drug called faricimab for people who have a specific type of wet age-related macular degeneration known as polypoidal choroidal vasculopathy. The goal is to see if adjusting the time between injections based on your individual needs can safely dry up fluid in the retina and improve vision.
Daegu, NamguAges 50 years+ - NCT07446582Recruiting
AI camera test for wet AMD detection
This study tests a new AI-powered camera that takes special pictures of the back of the eye to find signs of wet age-related macular degeneration (AMD) more easily. It compares images from people with wet AMD and healthy volunteers to see if the AI can spot the disease early.
Woodbridge, New JerseyAges 40 years+ - NCT07403825RecruitingPhase 4
Faricimab for wet AMD with subretinal material
This trial tests a new drug called Faricimab for people with a specific type of wet age-related macular degeneration (AMD) that has a buildup of material beneath the retina. The goal is to see if Faricimab can help clear this material and improve vision.
Córdoba, AndalusiaAges 50 years+ - NCT07338461Recruiting
High-resolution eye imaging study for healthy and eye disease volunteers
This study uses a special, high-resolution camera to take detailed pictures of the back of the eye. It is testing the camera's ability to see changes in the retina for people who are healthy or have age-related macular degeneration, diabetic retinopathy, or other conditions that affect autofluorescence patterns.
MilanAges 18 years+ - NCT02026843Recruiting
Testing eye fluid markers in chorioretinal eye diseases
This study looks at substances (“biomarkers”) in the clear fluid inside the eye to better understand several eye conditions that affect vision. Your results may help doctors learn how these diseases work and how treatments might be chosen.
Daegu, KyungsangpookdoAges 20–80 - NCT06875245RecruitingPhase 4
Comparing 8-Week vs 12-Week Faricimab for Wet AMD
This trial compares two different schedules (8 weeks vs 12 weeks) for follow-up injections of faricimab in people who are starting treatment for wet AMD. It aims to see if a longer gap between doses works just as well as the shorter interval.
PragueAges Any age - NCT07275840RecruitingPhase 2
Testing IBI302 for wet age-related macular degeneration
This study tests a new medicine called IBI302 for wet age-related macular degeneration (AMD). It aims to slow vision loss by targeting both blood vessel growth and inflammation. You might qualify if you have active wet AMD and have not had certain injections recently.
Shanghai, Shanghai MunicipalityAges 50 years+ - NCT06805474Recruiting
Study of a vision test for Stargardt and geographic atrophy
This study tests a new way to measure vision, called MLSDT, in people with normal sight or vision loss from Stargardt disease or geographic atrophy (a type of advanced age-related macular degeneration). Results will help doctors better understand how well patients can see.
Dallas, TexasAges 18 years+ - NCT07215234RecruitingPhase 1/Phase 2
Study of an injection for geographic atrophy in AMD
This study tests a single injection of an experimental drug (SAR446597) into the eye for people with geographic atrophy, a late-stage form of dry age-related macular degeneration. The goal is to see if it can safely slow vision loss.
Peoria, ArizonaAges 60 years+ - NCT07189169RecruitingPhase 3
Testing QA108 for intermediate AMD
This trial tests an investigational medicine (QA108) for people with intermediate age-related macular degeneration (AMD). It aims to slow or prevent progression of the disease by treating the deposits (drusen) in the center of the retina.
BeijingAges 45–85 - NCT06787482RecruitingPhase 1/Phase 2
Peptide therapy for retinitis pigmentosa
This trial tests a new peptide therapy for people with retinitis pigmentosa (RP), a genetic eye disease that causes vision loss. The goal is to see if the treatment is safe and can help slow or improve vision loss.
CairoAges Any age - NCT07158775RecruitingPhase 1/Phase 2
BS01 gene therapy for dry age-related macular degeneration
This trial tests a new gene therapy, BS01, given as an eye injection. It is for people with advanced dry age-related macular degeneration (AMD) that has caused geographic atrophy—damage to the central part of the retina. The study aims to see if the treatment is safe and can help slow vision loss.
Edison, New JerseyAges 50–85 - NCT07164378Recruiting
Study of an implant for vision loss from advanced AMD
This trial tests a small telescope implant for people with advanced age-related macular degeneration (AMD) in both eyes. It aims to improve central vision in the eye where the implant is placed.
MarseilleAges 55 years+ - NCT07135570Recruiting
My Eyes, My Light: Amar Chokh, Amar Alo
This trial is studying people living in Char Fasson, Bangladesh, to see who might have undiagnosed eye problems. It's a local screening program to catch eye issues early.
Char Fasson, BholaAges 35 years+ - NCT05675150Recruiting
Art-based program for adults with age-related vision loss
This trial tests whether an expressive arts-based program can help adults who have age-related macular degeneration (a common cause of vision loss) by supporting wellbeing and daily functioning. If you meet the language, vision, and health requirements, participating may help you benefit from a structured arts intervention.
Hong KongAges 50–80
Hear when a new Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for macular degeneration?
- Yes. Clin2 currently lists 164 recruiting macular degeneration studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a macular degeneration trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a macular degeneration trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Age-Related Macular Degeneration
- Neovascular Age-related Macular Degeneration
- Neovascular Age-Related Macular Degeneration (nAMD)
- Dry Age-related Macular Degeneration
- Wet Age-related Macular Degeneration
- Neovascular (Wet) Age-Related Macular Degeneration
- Age-related Macular Degeneration (ARMD)
- Exudative Age-Related Macular Degeneration
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.